Perspectives for IFAPP Academy in 2021
IFAPP Academy enters the New Year with renewed optimism after successfully overcoming the difficult and tragic circumstances we all underwent in the past 12 months and hoping COVID19 will soon be part of our memories. Our students’ resilience and commitment led to 125 new graduates from our program earning their certification in 2020. The success rate was comparable (83 %) to that of the past cohorts during 2107-2019. Metrics for knowledge gains and satisfaction were highly satisfactory and reflected in the new cohort’s number of applicants.
A total of 184 new students are registered in the 2021 program. We are pleased and acknowledge our sponsors and participants’ recognition and look forward to continuing with high-quality education and training activities leading to improved business performance.
We are committed to moving forward with our Vision and Values aiming to create a Community of Learners including alumni (about 400 already), Global Fellows, and members of the IFAPP National members associations as well as other biomedical professional involved in Medicines Development, providing additional CPD activities through our Value-Added Program. Around 2000 professionals are in our network.
In addition to the 2021 Core Program (Medical Affairs in Medicines Development Certification, Modules 1-6), we intend to:
- Confirm our New Programs’ initial success in collaboration with Tufts University CSDD and MAPS (Medical Affairs Professional Society).
- Achieve the state of the art in Digital Operations and e-learning.
- Position the IFAPP Academy as the beacon for Education and Training in Medicines Development
- Establish a Career Path in Medicines Development
- Ensure our organizational stability and a proper structure for long term operations.
- Continue the collaboration with King’s College London so that our graduates receive credits and continue their postgraduate education at King’s.
Considering the steady interannual increase in our annual cohorts’ size, we should ensure proper resources and functions are in place and continue developing synergies with our sponsors to further advance the metrics for success, including the assessment of behavioral changes and possible business impact of our program.
These challenging goals can only be achieved through the continuing implementation of our values: integrity, productive creativity, professionalism, global inclusiveness with internal/external partnership.
You are kindly invited to join us in this crusade to provide our society and stakeholders with competent professionals working in developing better medicines and leverage health globally.
Honorio Silva, MD, GFMD, FFPM (Hon)